Encapsulating RB in liposomes for drug delivery and combining it with the amino acids L-phenylalanine (Phe), L-aspartic acid (Asp), and glutamic acid (Glu) for targeting breast cancer cells that overexpress SLC7A5 has shown that the targeted liposomes inhibit breast cancer cell activity more effectively and shorten the cell cycle compared to free drug (Afsharzadeh et al., 2024). Here, SLC7A5 is linked to breast cancer.